Statins for people at low risk of cardiovascular disease

The Lancet

Volumn 380, Issue 9856, 2012, Pages 1816-

  Mascitelli, Luca ^a   Goldstein, Mark R ^b  

^a Medical Service   (Italy)

^b NCH Healthcare Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; HUMAN; ISCHEMIC HEART DISEASE; LETTER; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; BLOOD; NOTE; VASCULAR DISEASE;

CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; VASCULAR DISEASES;

EID: 84869426457     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)62025-X     Document Type: Letter

References (5)

1. Cholesterol Treatment Trialists' (CTT) Collaborators. The effect of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-90.
2. Mora S, Wenger NK, DeMicco DA, et al. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) Study. Circulation 2012; 125: 1979-87.
3. Bassan M, Panush N. Treating hypercholesterolemia-without the hype. Am J Cardiol 1997; 79: 1001-03.
4. Mascitelli L, Goldstein MR. Statins in dermatology: is nonmelanoma skin cancer the dark side of the moon? Int J Dermatol 2012; published online April 18. http://dx.doi.org/10.1111/j.1365-4632.2011.05067.x.
5. Rosenbaum D, Dallongeville J, Sabouret P, Bruckert E. Discontinuation of statin therapy due to muscular side effects: a survey in real life. Nutr Metab Cardiovasc Dis 2012; published online June 28. http://dx.doi.org/10.1016/j. numecd.2012.04.012.